Related Experiment Videos
The diseases treated with ECMO: focus on PPHN.
Kathryn N Farrow1, Paola Fliman, Robin H Steinhorn
1Division of Neonatology, Children's Memorial Hospital and Northwestern University, Chicago, IL, USA.
Seminars in Perinatology
|June 1, 2005
Summary
Persistent pulmonary hypertension of the newborn (PPHN) affects 0.2% of infants, causing respiratory failure. Understanding PPHN pathophysiology is key to developing new treatments for this condition.
Area of Science:
- Neonatology
- Pediatric Cardiology
- Pulmonary Medicine
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in neonates, often necessitating extracorporeal support.
- It arises from failed pulmonary vascular transition after birth, leading to respiratory distress and cyanosis in infants with structurally normal hearts.
- PPHN affects approximately 0.2% of live-born term infants.
Purpose of the Study:
- To elucidate the pathophysiology of PPHN.
- To explore novel treatment modalities for PPHN.
Main Methods:
- Review of existing literature on PPHN pathophysiology.
- Discussion of emerging therapeutic strategies.
Main Results:
- PPHN is categorized into three main types based on pulmonary vasculature abnormalities: abnormally constricted, structurally abnormal, and hypoplastic.
- Pathophysiology is linked to the timing of failed transition to extrauterine life during gestation.
- Specific conditions like meconium aspiration syndrome, respiratory distress syndrome, sepsis, congenital diaphragmatic hernia, and alveolar capillary dysplasia are associated with PPHN types.
Conclusions:
- PPHN pathophysiology varies depending on the underlying cause and developmental stage.
- Further research into PPHN pathophysiology is crucial for advancing treatment options.
- New treatment modalities hold promise for improving outcomes in neonates with PPHN.